1. US FDA. Adaptive design clinical trials for drug and biologics draft guidance. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Published 2010.
2. Miller E, Gallo P, He W, Kammerman L, et al. Best practices case studies for “less well-understood” adaptive designs. Therapeutic Innovation & Regulatory Science. In press.
3. US FDA. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Published 2006.
4. Husten L. Orexigen released interim data without approval of trial leaders. Forbes. 2015, March. http://www.forbes.com/sites/larryhusten/2015/03/03/orexigen-released-interim-data-without-approval-of-trial-leaders/
5. Jennison C, Turnbull B. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med. 2003;22:971–993.